ProQR clinical trial: Dominant RP

ProQR Therapeutics are conducting an ongoing clinical trial to investigate the safety and tolerability of QR-1123 in individuals living with Autosomal Dominant Retinitis Pigmentosa, due to the P23H mutation in the RHO gene.

Aurora is a 12-month trial designed to assess if differing doses of investigational gene therapy QR-1123 are safe, as well as to determine whether or not they elicit any improvements in visual function or retinal structure. Participants in the study receive a single intravitreal injection or as many as 4 doses and the effects of these treatments will be measured to confirm a safe and effective therapeutic dose.

ProQR have a page on their website describing the Aurora clinical trial, rationale and design, along with other links to get additional details about Aurora. Click here to learn more about the Aurora phase 1/2 clinical trial and what this trial means for people living with Autosomal Dominant Retinitis Pigmentosa.


To keep up to date with our news and activities,
please leave your details below

Please indicate your consent for Retina International to contact you via the email address listed for the purposes of general alerts and newsletters.

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.